Matthews Holly, Deakin Jon, Rajab May, Idris-Usman Maryam, Nirmalan Niroshini J
Environment and Life sciences, University of Salford, Greater Manchester, United Kingdom.
PLoS One. 2017 Mar 3;12(3):e0173303. doi: 10.1371/journal.pone.0173303. eCollection 2017.
The widespread introduction of artemisinin-based combination therapy has contributed to recent reductions in malaria mortality. Combination therapies have a range of advantages, including synergism, toxicity reduction, and delaying the onset of resistance acquisition. Unfortunately, antimalarial combination therapy is limited by the depleting repertoire of effective drugs with distinct target pathways. To fast-track antimalarial drug discovery, we have previously employed drug-repositioning to identify the anti-amoebic drug, emetine dihydrochloride hydrate, as a potential candidate for repositioned use against malaria. Despite its 1000-fold increase in in vitro antimalarial potency (ED50 47 nM) compared with its anti-amoebic potency (ED50 26-32 uM), practical use of the compound has been limited by dose-dependent toxicity (emesis and cardiotoxicity). Identification of a synergistic partner drug would present an opportunity for dose-reduction, thus increasing the therapeutic window. The lack of reliable and standardised methodology to enable the in vitro definition of synergistic potential for antimalarials is a major drawback. Here we use isobologram and combination-index data generated by CalcuSyn software analyses (Biosoft v2.1) to define drug interactivity in an objective, automated manner. The method, based on the median effect principle proposed by Chou and Talalay, was initially validated for antimalarial application using the known synergistic combination (atovaquone-proguanil). The combination was used to further understand the relationship between SYBR Green viability and cytocidal versus cytostatic effects of drugs at higher levels of inhibition. We report here the use of the optimised Chou Talalay method to define synergistic antimalarial drug interactivity between emetine dihydrochloride hydrate and atovaquone. The novel findings present a potential route to harness the nanomolar antimalarial efficacy of this affordable natural product.
以青蒿素为基础的联合疗法的广泛应用促成了近期疟疾死亡率的下降。联合疗法具有一系列优势,包括协同作用、降低毒性以及延缓耐药性产生。不幸的是,抗疟联合疗法受到具有不同靶标途径的有效药物种类日益减少的限制。为了加快抗疟药物的研发,我们之前采用药物重新定位的方法,确定抗阿米巴药物盐酸依米丁水合物为一种重新用于抗疟的潜在候选药物。尽管其体外抗疟效力(半数有效浓度47 nM)相较于抗阿米巴效力(半数有效浓度26 - 32 μM)提高了1000倍,但该化合物的实际应用因剂量依赖性毒性(呕吐和心脏毒性)而受到限制。鉴定一种协同伴侣药物将带来降低剂量的机会,从而扩大治疗窗口。缺乏可靠且标准化的方法来在体外确定抗疟药物的协同潜力是一个主要缺陷。在此,我们使用由CalcuSyn软件分析(Biosoft v2.1)生成的等效线图和联合指数数据,以客观、自动化的方式定义药物相互作用。该方法基于Chou和Talalay提出的中位效应原理,最初使用已知的协同组合(阿托伐醌 - 氯胍)进行抗疟应用验证。该组合被用于进一步了解在更高抑制水平下SYBR Green活力与药物的杀细胞和细胞生长抑制作用之间的关系。我们在此报告使用优化后的Chou Talalay方法来定义盐酸依米丁水合物与阿托伐醌之间的协同抗疟药物相互作用。这些新发现为利用这种价格低廉的天然产物的纳摩尔抗疟效力提供了一条潜在途径。